Effectiveness of psychotherapeutic, pharmacological, and combined treatments for chronic depression: A systematic review (METACHRON)

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Kriston, Levente ^a   von Wolff, Alessa ^a   Hölzel, Lars ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ACUPUNCTURE; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DEPRESSION; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; EXERCISE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PHOTOTHERAPY; PSYCHODYNAMICS; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHAM PROCEDURE; SYMPTOM CHECKLIST 90; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; ADULT; CHRONIC DISEASE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; REVIEW; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78549279175     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-95     Document Type: Article

References (46)

1. Klein DN. Chronic Depression: Diagnosis and Classification. Curr Dir Psychol Sci 2010, 19:96-100.
2. Boland RJ, Keller MB. Course and outcome of depression. Handbook of depression 2002, 43-60. New York: Guilford Press, Gotlib IH, Hammen CL.
3. Gilmer WS, Trivedi MH, Rush AJ, Wisniewski SR, Luther J, Howland RH, Yohanna D, Khan A, Alpert J. Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand 2005, 112:425-433. 10.1111/j.1600-0447.2005.00633.x, 16279871.
4. Keller MB, Lavori PW, Mueller TI, Endicott J, William Coryell W, Hirschfeld RMA, Shea T. Time to recovery, chronicity and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992, 53:777-784.
5. Kocsis JH, Gelenberg AJ, Rothbaum B, Klein DN, Trivedi MH, Manber R, Keller MB, Howland R, Thase ME. Chronic forms of major depression are still undertreated in the 21st century: Systematic assessment of 801 patients presenting for treatment. J Affect Disord 2008, 110:55-61. 10.1016/j.jad.2008.01.002, 18272232.
6. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States. Results From the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
7. Markowitz JC, Moran ME, Kocsis JH, Frances AJ. Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients. J Affect Disord 1991, 24:63-71.
8. Arnow BA, Constantino MJ. Effectiveness of Psychotherapy and Combination Treatment for Chronic Depression. J Clin Psychol 2003, 59:893-905. 10.1002/jclp.10181, 12858430.
9. Williams JW, Barrett J, Oxman T, Frank E, Katon W, Sullivan M, Cornell J, Sengupta A. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA 2000, 284:1519-1526. 10.1001/jama.284.12.1519, 11000645.
10. Barrett JE, Williams JW, Oxman TE, Frank E, Katon W, Sullivan M, Hegel MT, Cornell JE, Sengupta ASB, J E, Williams JW, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001, 50:405-412.
11. Ravindran AV, Anisman H, Merali Z, Charbonneau Y, Telner J, Bialik RJ, Wiens A, Ellis J, Griffiths J. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Am J Psychiatry 1999, 156:1608-1617.
12. Dunner DL, Schmaling KB, Hendrickson H, Becker J, Lehman A, Bea C. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression 1996, 4:34-41. 10.1002/(SICI)1522-7162(1996)4:1<34::AID-DEPR4>3.0.CO;2-F, 9160652.
13. Hellerstein DJ, Little SAS, Samstag LW, Batchelder S, Muran JC, Fedak M, Kr D, Rosenthal RN, Winston A. Adding group psychotherapy to medication treatment in dysthymia: A randomized prospective pilot study. J Psychother Pract Res 2001, 10:93-103.
14. Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, Bell B, Mills M, Chalklin L, Wallik D, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 2002, 68:317-330. 10.1016/S0165-0327(01)00343-3, 12063159.
15. Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Disord 2005, 89:167-175. 10.1016/j.jad.2005.10.001, 16263177.
16. Schramm E, Schneider D, Zobel I, van Calker D, Dykierek P, Kech S, Harter M, Berger M. Efficacy of Interpersonal Psychotherapy plus pharmacotherapy in chronically depressed inpatients. J Affect Disord 2008, 109:65-73. 10.1016/j.jad.2007.10.013, 18067973.
17. Miller IW, Norman WH, Keitner GI. Combined treatment for patients with double depression. Psychother Psychosom 1999, 68:180-185. 10.1159/000012330, 10396008.
18. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.[Erratum appears in N Engl J Med 2001 Jul 19;345(3):232]. N Engl J Med 2000, 342:1462-1470. 10.1056/NEJM200005183422001, 10816183.
19. Mello MF, Myczowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. 2001, 10:117-123.
20. Markowitz JC. Psychotherapy of dysthymia. Am J Psychiatry 1994, 151:1114-1121.
21. Lima MS, Hotopf M. Pharmacotherapy for dysthymia. Cochrane Database Syst Rev 2003, 3:CD004047.
22. Lima MS, Moncrieff J, Soares BGO. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev 2005, 2:CD001130.
23. Michalak EE, Lam RW. Breaking the myths: New treatment approaches for chronic depression. Can J Psychiatry 2002, 47:635-643.
24. World Health Organization International Statistical Classification of Diseases, 10th Revision (ICD-10). 1992, Geneva: World Health Organization, World Health Organization.
25. APA - American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders - DSM-IV-TR. 2000, Washington, DC: American Psychiatric Association, APA - American Psychiatric Association.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62. 10.1136/jnnp.23.1.56, 495331, 14399272.
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389. 10.1192/bjp.134.4.382, 444788.
28. National Institute of Mental Health 028 CGI. Clinical Global Impressions. ECDEU Assessment for psychopharmacology Rev Ed 1976:217-222. Rockville: MD: U.S. Department of Health, Education, and Welfare, Guy W, National Institute of Mental Health.
29. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for measuring Depression. Arch Gen Psychiatry 1961, 4:561-571.
30. Derogatis LR. SCL-90-R, administration, scoring & procedures manual for the R(evised) version. 1977, Baltimore: John Hopkins University School of Medicine.
31. Grogan S, Conner M, Willits D, Norman P. Development of a questionnaire to measure patients' satisfaction with general practitioners' services. Br J Gen Pract 1995, 45:525-529. 1239403, 7492421.
32. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL Group. Qual Life Res 2004, 13:229-310.
33. Higgins JPT, Green S, . (Eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. 2009, The Cochrane Collaboration, (Eds).
34. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005, 20:49-52. 10.1097/00004850-200501000-00010, 15602117.
35. Khan KS, Ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking Systematic Reviews of Research on Effectiveness, CRD's Guidance for those Carrying Out or Commissioning Reviews. CRD Report Number 4 2001, Heslington, York: NHS Centre for Reviews and Dissemination, University of York, 2.
36. Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care. Meta-analysis in context. 2003, London: BMJ Publishing Group.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
38. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
39. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. Systematic reviews in health care: meta-analysis in context 2003, 248-282. London: BMJ Publishing Group, Egger M, Smith GD, Altman DG.
40. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691. 10.1016/S0895-4356(97)00049-8, 9250266.
41. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several stud-ies in meta-analysis. Systematic reviews in health care: meta-analysis in context 2003, 313-335. London: BMJ Publishing Group, Egger M, Smith GD, Altman DG.
42. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472. 10.1136/bmj.326.7387.472, 150178, 12609941.
43. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999, 18:2693-2708. 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V, 10521860.
44. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324. 10.1002/sim.1201, 12210616.
45. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008, 26:753-767. 10.2165/00019053-200826090-00006, 18767896.
46. Moher D, Liberati A, Tetzlaff J, Altman DG, . The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med 2009, 151:264-269. The PRISMA Group.